American Capital Advisory’s Abivax ABVX Stock Holding History

American Capital Advisory’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$667	Buy	+5	New	+$566	﹤0.01%	892

Other funds holding ABVX

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

ACT Capital Management Wayne, Pennsylvania $153M AUM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Andera Partners Paris $206M AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Syquant Capital SAS Paris, France $447M AUM 13.04% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

T3 Companies New York $93.7M AUM

American Capital Advisory's ABVX Position: Q2 2026 in Review

American Capital Advisory opened a new position in Abivax (ABVX) in Q2 2026: 5 shares worth $667. The stake represents ﹤0.01% of the portfolio and ranks #892 among its holdings.

52 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

American Capital Advisory held 5 shares of Abivax worth $667 as of Q2 2026.
Abivax was a new American Capital Advisory position in Q2 2026.
Abivax made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #892 holding.
52 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.